Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
AMGEN INC (AMGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines"
10/05/2023 8-K Other Events  Interactive Data
08/03/2023 8-K Quarterly results
Docs: "AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS"
05/18/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/16/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. - Amgen today issued the following statement in response to the U.S. Federal Trade Commission's complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc: “Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare diseases in the U.S. and around the world. We have been working cooperatively over the past several months to address the questions raised by the FTC's investigative staff and believe we have overwhelmingly demonstrated that this combination poses no legitimate competitive issues. The medicines offered by Amgen and Horizon genera..."
04/27/2023 8-K Quarterly results
03/09/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Third Amended and Restated Credit Agreement, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent",
"Third Amended and Restated Credit Agreement, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent"
03/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Officer’s Certificate of the Company, including forms of the Company’s 5.250% Senior Notes due 2025, 5.507% Senior Notes due 2026, 5.150% Senior Notes due 2028, 5.250% Senior Notes due 2030, 5.250% Senior Notes due 2033, 5.600% Senior Notes due 2043, 5.650% Senior Notes due 2053 and 5.750% Senior Notes due 2063",
"Opinion of Latham & Watkins LLP"
01/31/2023 8-K Quarterly results
Docs: "AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT",
"AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS",
"Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy"
12/22/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Term Loan Credit Agreement, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto",
"Term Loan Credit Agreement, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto"
12/12/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Transaction Agreement, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc",
"Appendix 3 to the Rule 2.7 Announcement, (Conditions Appendix)",
"Bridge Credit Agreement, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A. and Bank of America, N.A., as lead arrangers and book runners, and the other banks party thereto",
"Rule 2.7 Announcement"
12/02/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/03/2022 8-K Appointed a new director
Docs: "AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS"
05/18/2022 8-K Quarterly results
04/27/2022 8-K Quarterly results
Docs: "AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS",
"Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy"
02/24/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Form of ASR Agreement",
"Form of ASR Agreement"
02/22/2022 8-K Quarterly results
02/07/2022 8-K Quarterly results
01/31/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
Docs: "Amendment No. 3 to the Exclusive License and Collaboration Agreement, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)"
11/02/2021 8-K Quarterly results
Docs: "AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS"
08/09/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS"
07/29/2021 8-K Quarterly results
07/27/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "AMGEN TO ACQUIRE PRIVATELY HELD TENEOBIO FOR $900 MILLION IN CASH WITH FUTURE CONTINGENT MILESTONE PAYMENTS Acquisition Complements Amgen's Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer"
06/01/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy